"纤维肌痛--有什么新方法吗?

IF 4.5 2区 医学 Q1 RHEUMATOLOGY Best Practice & Research in Clinical Rheumatology Pub Date : 2024-03-01 DOI:10.1016/j.berh.2024.101933
{"title":"\"纤维肌痛--有什么新方法吗?","authors":"","doi":"10.1016/j.berh.2024.101933","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>Approaching patients with fibromyalgia (FM) is challenging due to the limited availability of scientifically proven effective therapies.</p></div><div><h3>Objective</h3><p><span><span><span><span><span>Review the treatments in use for FM and present new knowledge that could benefit these patients. Non-pharmacological interventions are recommended as the first line of treatment: aerobic exercise, cognitive behavioral therapy and patient education, all aimed at improving pain and other symptoms. Additional approaches have been studied, such as, </span>digital health<span><span> interventions, combined treatments, noninvasive neuromodulation<span>, and others. Concerning pharmacological therapy, the mechanism of action of the medications currently used is to promote </span></span>pain modulation. Medications approved by Food and Drug Administration are </span></span>duloxetine, </span>milnacipran and </span>pregabalin<span><span>. Amitriptyline, </span>cyclobenzaprine<span><span>, gabapentin and </span>naltrexone<span> are considered for off-label use. Cannabinoids, </span></span></span></span>vitamin D supplementation are still controversial and further research is needed.</p></div><div><h3>Conclusion</h3><p>The combination of therapies, whether old, recent or reformulated, are the most effective strategy for managing symptoms in patients with fibromyalgia. Key Words: fibromyalgia, treatment, nonpharmacological interventions, pharmacological treatment.</p></div>","PeriodicalId":50983,"journal":{"name":"Best Practice & Research in Clinical Rheumatology","volume":null,"pages":null},"PeriodicalIF":4.5000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"“Fibromyalgia – are there any new approaches?”\",\"authors\":\"\",\"doi\":\"10.1016/j.berh.2024.101933\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><p>Approaching patients with fibromyalgia (FM) is challenging due to the limited availability of scientifically proven effective therapies.</p></div><div><h3>Objective</h3><p><span><span><span><span><span>Review the treatments in use for FM and present new knowledge that could benefit these patients. Non-pharmacological interventions are recommended as the first line of treatment: aerobic exercise, cognitive behavioral therapy and patient education, all aimed at improving pain and other symptoms. Additional approaches have been studied, such as, </span>digital health<span><span> interventions, combined treatments, noninvasive neuromodulation<span>, and others. Concerning pharmacological therapy, the mechanism of action of the medications currently used is to promote </span></span>pain modulation. Medications approved by Food and Drug Administration are </span></span>duloxetine, </span>milnacipran and </span>pregabalin<span><span>. Amitriptyline, </span>cyclobenzaprine<span><span>, gabapentin and </span>naltrexone<span> are considered for off-label use. Cannabinoids, </span></span></span></span>vitamin D supplementation are still controversial and further research is needed.</p></div><div><h3>Conclusion</h3><p>The combination of therapies, whether old, recent or reformulated, are the most effective strategy for managing symptoms in patients with fibromyalgia. Key Words: fibromyalgia, treatment, nonpharmacological interventions, pharmacological treatment.</p></div>\",\"PeriodicalId\":50983,\"journal\":{\"name\":\"Best Practice & Research in Clinical Rheumatology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.5000,\"publicationDate\":\"2024-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Best Practice & Research in Clinical Rheumatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1521694224000044\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"RHEUMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Best Practice & Research in Clinical Rheumatology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1521694224000044","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

导言:纤维肌痛(FM)患者的治疗具有挑战性,因为经科学证实的有效疗法有限:回顾纤维肌痛的现有治疗方法,并介绍可使这些患者受益的新知识。建议将非药物干预作为第一线治疗方法:有氧运动、认知行为疗法和患者教育,这些方法都旨在改善疼痛和其他症状。此外,还研究了其他方法,如数字健康干预、综合治疗、非侵入性神经调节等。关于药物治疗,目前使用的药物的作用机制是促进疼痛调节。经美国食品和药物管理局批准的药物有度洛西汀、米那西普兰和普瑞巴林。阿米替林、环苯扎林、加巴喷丁和纳曲酮可考虑在标签外使用。大麻素、维生素 D 补充剂仍存在争议,需要进一步研究:综合疗法,无论是旧疗法、新疗法还是重新配制的疗法,都是控制纤维肌痛患者症状的最有效策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
“Fibromyalgia – are there any new approaches?”

Introduction

Approaching patients with fibromyalgia (FM) is challenging due to the limited availability of scientifically proven effective therapies.

Objective

Review the treatments in use for FM and present new knowledge that could benefit these patients. Non-pharmacological interventions are recommended as the first line of treatment: aerobic exercise, cognitive behavioral therapy and patient education, all aimed at improving pain and other symptoms. Additional approaches have been studied, such as, digital health interventions, combined treatments, noninvasive neuromodulation, and others. Concerning pharmacological therapy, the mechanism of action of the medications currently used is to promote pain modulation. Medications approved by Food and Drug Administration are duloxetine, milnacipran and pregabalin. Amitriptyline, cyclobenzaprine, gabapentin and naltrexone are considered for off-label use. Cannabinoids, vitamin D supplementation are still controversial and further research is needed.

Conclusion

The combination of therapies, whether old, recent or reformulated, are the most effective strategy for managing symptoms in patients with fibromyalgia. Key Words: fibromyalgia, treatment, nonpharmacological interventions, pharmacological treatment.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
9.40
自引率
0.00%
发文量
43
审稿时长
27 days
期刊介绍: Evidence-based updates of best clinical practice across the spectrum of musculoskeletal conditions. Best Practice & Research: Clinical Rheumatology keeps the clinician or trainee informed of the latest developments and current recommended practice in the rapidly advancing fields of musculoskeletal conditions and science. The series provides a continuous update of current clinical practice. It is a topical serial publication that covers the spectrum of musculoskeletal conditions in a 4-year cycle. Each topic-based issue contains around 200 pages of practical, evidence-based review articles, which integrate the results from the latest original research with current clinical practice and thinking to provide a continuous update. Each issue follows a problem-orientated approach that focuses on the key questions to be addressed, clearly defining what is known and not known. The review articles seek to address the clinical issues of diagnosis, treatment and patient management. Management is described in practical terms so that it can be applied to the individual patient. The serial is aimed at the physician in both practice and training.
期刊最新文献
Global RA treatment recommendations: An update from the various international societies. Clinical manifestations of rheumatoid arthritis, including comorbidities, complications, and long-term follow-up. Role of rheumatoid arthritis registries worldwide: What have they taught us? Explainable biology for improved therapies in precision medicine: AI is not enough. Preface to genomics of rheumatic disease.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1